Modulation of CD8+ T cell responses to AAV vectors with IgG-derived MHC class II epitopes
Daniel J. Hui(Children's Hospital of Philadelphia), Federico Mingozzi(Spark Therapeutics (United States)), Alex Tai(Children's Hospital of Philadelphia), David W. Scott(Spinal Cord Injury BC), George Buchlis(University of Pennsylvania), Leslie P. Cousens(Providence College), Etiena Basner‐Tschakarjan(Children's Hospital of Philadelphia), Jonathan D. Finn(Children's Hospital of Philadelphia), Anne S. De Groot(Providence College), Yifeng Chen(Children's Hospital of Philadelphia), Robert J. Davidson(Children's Hospital of Philadelphia), Gary C. Pien(Children's Hospital of Philadelphia), Virginia Haurigot(Spark Therapeutics (United States)), Shangzhen Zhou(Penn Presbyterian Medical Center), Mustafa N. Yazicioglu(Children's Hospital of Philadelphia)
Cited by 45
Related Papers
Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance
|Proceedings of the National Academy of Sciences|2014|435
Overcoming Preexisting Humoral Immunity to AAV Using Capsid Decoys
|Science Translational Medicine|2013|346
Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy
|Journal of Clinical Investigation|2013|232
Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells
|Blood|2013|160
Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid α-glucosidase
|Science Translational Medicine|2017|133